At the news
? NEUTRALIMPACT 2/10 144 filed Nov 16, 2026 at 11:17 ET
Vertex Pharmaceuticals director Nancy Thornberry filed a Form 144 notice of intent to sell 1,000 shares of common stock, with an estimated aggregate market value of approximately $547,860 based on the filing. The shares were acquired through restricted stock vesting in December 2024 and May 2025. This is a routine, small disposition relative to the company's $137.6B market cap and the director's likely total holdings.
- Nancy Thornberry, a director of Vertex Pharmaceuticals, filed a Form 144 on November 16, 2026.
- The proposed sale is for 1,000 shares of common stock.
- Estimated aggregate market value of the sale is $547,860.
- Shares were acquired via restricted stock vesting on December 5, 2024 (499 shares) and May 1, 2025 (501 shares).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access